Is Retevmo Monotherapy Effective for Lung Cancer?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On August 4, 2023, Eli Lilly announced the results of the Phase 3 LIBRETTO-431 clinical trial evaluating first-line Retevmo (selpercatinib) monotherapy in patients with RET fusion-positive metastatic or advanced non-small cell lung cancer (NSCLC).
The LIBRETTO-431 Phase 3 trial randomized 261 treatment-naive patients with RET fusion-positive metastatic or advanced NSCLC to receive either Retevmo monotherapy or anti-PD-1 antibody therapy combined with chemotherapy. The primary endpoint was progression-free survival (PFS), and secondary endpoints included overall survival (OS), objective response rate (ORR), duration of response (DOR), and intracranial objective response rate.
This trial is the first to compare a targeted therapy against anti-PD-1 therapy plus chemotherapy in patients with a specific genetic alteration. The results showed that Retevmo monotherapy significantly prolonged PFS compared to the control group. Detailed findings will be presented at an upcoming medical conference and published in a peer-reviewed journal.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4